Acute myeloid leukemia: 2019 update on risk-stratification and management
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Acute myeloid leukemia: 2019 update on risk-stratification and management
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF HEMATOLOGY
Volume 93, Issue 10, Pages 1267-1291
Publisher
Wiley
Online
2018-10-17
DOI
10.1002/ajh.25214
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults
- (2018) Stephanie B. Tsai et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia
- (2018) H. Joachim Deeg et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia: A National Population-Based Cohort Study
- (2018) Lene Sofie Granfeldt Østgård et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Glutaminolysis is a metabolic dependency in FLT3ITDacute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition
- (2018) Paolo Gallipoli et al. BLOOD
- Associations between cohabitation status, treatment, and outcome in AML patients: a national population-based study
- (2018) Lene Sofie Granfeldt Østgård et al. BLOOD
- HighNPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML
- (2018) Sanjay S. Patel et al. BLOOD
- The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia
- (2018) Eytan M. Stein et al. BLOOD
- Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia
- (2018) Raphael Itzykson et al. BLOOD
- Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
- (2018) Gerrit J. Schuurhuis et al. BLOOD
- Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000
- (2018) Hagop M. Kantarjian et al. CANCER
- Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California
- (2018) Gwendolyn Ho et al. CANCER
- Investigational CD33-targeted therapeutics for acute myeloid leukemia
- (2018) Roland B. Walter EXPERT OPINION ON INVESTIGATIONAL DRUGS
- NPM1 mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents
- (2018) Pedro Henrique Prata et al. HAEMATOLOGICA
- Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations
- (2018) Sylvie D. Freeman et al. JOURNAL OF CLINICAL ONCOLOGY
- Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia
- (2018) Kiyomi Morita et al. JOURNAL OF CLINICAL ONCOLOGY
- CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
- (2018) Jeffrey E. Lancet et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms
- (2018) Anna B. Halpern et al. LEUKEMIA
- Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies
- (2018) Ann-Kathrin Eisfeld et al. LEUKEMIA
- Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
- (2018) Naval Daver et al. LEUKEMIA
- New drugs in AML: uses and abuses
- (2018) Elihu H. Estey et al. LEUKEMIA
- Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial
- (2018) Peter Paschka et al. LEUKEMIA
- Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study
- (2018) Yasuhiko Harada et al. LEUKEMIA RESEARCH
- Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations
- (2018) Jesse J. Salk et al. NATURE REVIEWS GENETICS
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
- (2018) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Minimal Residual Disease in Acute Myeloid Leukemia
- (2018) Mojca Jongen-Lavrencic et al. NEW ENGLAND JOURNAL OF MEDICINE
- NPM1 mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents
- (2018) Pedro Henrique Prata et al. HAEMATOLOGICA
- Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial
- (2018) Frederick Fasslrinner et al. Lancet Haematology
- Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2
- (2018) Amir T. Fathi et al. JAMA Oncology
- Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm
- (2017) Roland B. Walter et al. HAEMATOLOGICA
- CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children’s Oncology Group Trial AAML0531
- (2017) Jatinder K. Lamba et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of Education and Income on Treatment and Outcome in Patients With Acute Myeloid Leukemia in a Tax-Supported Health Care System: A National Population-Based Cohort Study
- (2017) Lene Sofie Granfeldt Østgård et al. JOURNAL OF CLINICAL ONCOLOGY
- Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
- (2017) Bart L. Scott et al. JOURNAL OF CLINICAL ONCOLOGY
- Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)
- (2017) Nicolaus Kröger et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission
- (2017) Xavier Thomas et al. JOURNAL OF CLINICAL ONCOLOGY
- Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
- (2017) Margaret R. O'Donnell et al. Journal of the National Comprehensive Cancer Network
- Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse
- (2017) P Boddu et al. LEUKEMIA
- Is there a need for morphologic exam to detect relapse in AML if multi-parameter flow cytometry is employed?
- (2017) Y Zhou et al. LEUKEMIA
- How good are we at predicting the fate of someone with acute myeloid leukaemia?
- (2017) E Estey et al. LEUKEMIA
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia
- (2017) S Jaramillo et al. Blood Cancer Journal
- Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm
- (2017) Roland B. Walter et al. HAEMATOLOGICA
- Development and Validation of a Novel Acute Myeloid Leukemia–Composite Model to Estimate Risks of Mortality
- (2017) Mohamed L. Sorror et al. JAMA Oncology
- Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia
- (2016) A. K. Burnett et al. BLOOD
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia
- (2016) G. Olombel et al. BLOOD
- Comprehensive mutational profiling of core binding factor acute myeloid leukemia
- (2016) N. Duployez et al. BLOOD
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation
- (2016) M Elsawy et al. BONE MARROW TRANSPLANTATION
- Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia
- (2016) C. Craddock et al. HAEMATOLOGICA
- Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial
- (2016) Sergio Amadori et al. JOURNAL OF CLINICAL ONCOLOGY
- Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease–Based Definition of Complete Remission?
- (2016) Daisuke Araki et al. JOURNAL OF CLINICAL ONCOLOGY
- Prevalence and characteristics of survivors from acute myeloid leukemia in Sweden
- (2016) G Juliusson et al. LEUKEMIA
- Prediction of CR following a second course of ‘7+3’ in patients with newly diagnosed acute myeloid leukemia not in CR after a first course
- (2016) M Othus et al. LEUKEMIA
- Effect of measurable (‘minimal’) residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia
- (2016) M Othus et al. LEUKEMIA
- A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials
- (2016) G Montalban-Bravo et al. LEUKEMIA
- Acute myeloid leukemia therapy and the chosen people
- (2016) E Estey et al. LEUKEMIA
- Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia
- (2016) N Khan et al. LEUKEMIA
- Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia
- (2016) U Krug et al. LEUKEMIA
- Cord-Blood Transplantation in Patients with Minimal Residual Disease
- (2016) Filippo Milano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessment of Minimal Residual Disease in Standard-Risk AML
- (2016) Adam Ivey et al. NEW ENGLAND JOURNAL OF MEDICINE
- TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
- (2016) John S. Welch et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic Classification and Prognosis in Acute Myeloid Leukemia
- (2016) Elli Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia
- (2016) George S. Laszlo et al. Oncotarget
- Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
- (2016) Koichi Takahashi et al. Oncotarget
- Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia
- (2016) C. Craddock et al. HAEMATOLOGICA
- Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation
- (2016) Stephanie J. Lee et al. JAMA Oncology
- Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States
- (2015) Bruno C. Medeiros et al. ANNALS OF HEMATOLOGY
- What came first: MDS or AML?
- (2015) M. J. Walter BLOOD
- Hematopoietic stem cell transplantation for patients with AML in first complete remission
- (2015) J. J. Cornelissen et al. BLOOD
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
- (2015) H. Dombret et al. BLOOD
- Current challenges in clinical development of "targeted therapies": the case of acute myeloid leukemia
- (2015) E. Estey et al. BLOOD
- Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia
- (2015) Anna B. Halpern et al. BLOOD
- Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML
- (2015) T. N. Wong et al. BLOOD
- How I treat refractory and early relapsed acute myeloid leukemia
- (2015) F. Thol et al. BLOOD
- A randomized comparison of daunorubicin 90 mg/m 2 vs 60 mg/m 2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients
- (2015) Alan K. Burnett et al. BLOOD
- Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG
- (2015) R. B. Walter et al. HAEMATOLOGICA
- Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact on Outcome in Acute Myeloid Leukemia
- (2015) Xueyan Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Significance ofNPM1Mutations in the Absence ofFLT3–Internal Tandem Duplication in Older Patients With Acute Myeloid Leukemia: A SWOG and UK National Cancer Research Institute/Medical Research Council Report
- (2015) Fabiana Ostronoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
- (2015) Christoph Röllig et al. LANCET ONCOLOGY
- Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine
- (2015) J Desoutter et al. LEUKEMIA
- New drug approvals in acute myeloid leukemia: what’s the best end point?
- (2015) E Estey et al. LEUKEMIA
- Immunotherapy for Acute Myeloid Leukemia
- (2015) Felix S. Lichtenegger et al. SEMINARS IN HEMATOLOGY
- Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG
- (2015) R. B. Walter et al. HAEMATOLOGICA
- Alternative donor transplantation for adults with acute leukemia
- (2014) Frederick R. Appelbaum BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Acute myeloid leukemia ontogeny is defined by distinct somatic mutations
- (2014) R. C. Lindsley et al. BLOOD
- International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- (2014) Gail J. Roboz et al. JOURNAL OF CLINICAL ONCOLOGY
- Comorbidity-Age Index: A Clinical Measure of Biologic Age Before Allogeneic Hematopoietic Cell Transplantation
- (2014) Mohamed L. Sorror et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
- (2014) Robert K Hills et al. LANCET ONCOLOGY
- The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial
- (2014) M Lazenby et al. LEUKEMIA
- Leukemic Stem Cell Frequency: A Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia
- (2014) Monique Terwijn et al. PLoS One
- Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia
- (2013) S. Bertoli et al. BLOOD
- Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants
- (2013) A. Galanis et al. BLOOD
- Sense and nonsense of high-dose cytarabine for acute myeloid leukemia
- (2013) B. Lowenberg BLOOD
- The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA
- (2013) R. F. Schlenk et al. BLOOD
- Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia
- (2013) E. Jourdan et al. BLOOD
- MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial
- (2013) H.-H. Zhu et al. BLOOD
- Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia
- (2013) Sylvie D. Freeman et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial
- (2013) Hubert Serve et al. JOURNAL OF CLINICAL ONCOLOGY
- Frequency of Allogeneic Hematopoietic Cell Transplantation Among Patients With High- or Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission
- (2013) Raya Mawad et al. JOURNAL OF CLINICAL ONCOLOGY
- Curability of Patients With Acute Myeloid Leukemia Who Did Not Undergo Transplantation in First Remission
- (2013) Alan K. Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study
- (2013) Monique Terwijn et al. JOURNAL OF CLINICAL ONCOLOGY
- Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial
- (2013) Alan K. Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson
- (2013) M Othus et al. LEUKEMIA
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia
- (2012) A. Quintas-Cardama et al. BLOOD
- Acute myeloid leukemia stem cells and CD33-targeted immunotherapy
- (2012) R. B. Walter et al. BLOOD
- Acute Myeloid Leukemia and Myelodysplastic Syndromes After Radiation Therapy Are Similar to De Novo Disease and Differ From Other Therapy-Related Myeloid Neoplasms
- (2012) Valentina Nardi et al. JOURNAL OF CLINICAL ONCOLOGY
- Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment
- (2011) Roland B. Walter et al. JOURNAL OF CLINICAL ONCOLOGY
- First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
- (2011) Eric J. Feldman et al. JOURNAL OF CLINICAL ONCOLOGY
- Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy
- (2010) F. Ravandi et al. BLOOD
- Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome
- (2010) Celeste Bello et al. CANCER
- Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation
- (2010) Ted A. Gooley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry
- (2008) G. Juliusson et al. BLOOD
- Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients
- (2008) M. A. Sekeres et al. BLOOD
- Relapse and death during first remission in acute myeloid leukemia
- (2008) M. Yanada et al. HAEMATOLOGICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search